Pacific Edge Limited (PFGTF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pacific Edge Limited (PFGTF) with AI Score 52/100 (Hold). Pacific Edge Limited is a cancer diagnostic company focused on early detection and management of cancers. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Pacific Edge Limited (PFGTF) Healthcare & Pipeline Overview
Pacific Edge Limited, a New Zealand-based cancer diagnostics firm, specializes in genomic urine tests like Cxbladder for the early detection and management of bladder cancer across New Zealand, the United States, Australia, and Singapore. With a focus on non-invasive cancer detection, the company operates in the competitive medical diagnostics sector.
Investment Thesis
Pacific Edge Limited presents a focused investment opportunity within the cancer diagnostics market, particularly in bladder cancer detection. The company's Cxbladder suite of genomic urine tests offers a non-invasive alternative to traditional methods. Key value drivers include the continued adoption of Cxbladder by urologists in the United States, Australia, New Zealand, and Singapore, as well as the successful development and commercialization of new diagnostic tools for other cancers, such as Cxcolorectal. The company's gross margin of 26.2% indicates potential for improved profitability as sales scale. Ongoing catalysts include expanding clinical utility and securing favorable reimbursement policies. Potential risks include competition from established diagnostic companies, regulatory hurdles, and the need for additional funding to support research and commercialization efforts. The company's negative P/E ratio of -4.78 and negative profit margin of -205.3% highlight the importance of achieving profitability through revenue growth and cost management.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.24 billion, reflecting its position as a smaller player in the diagnostics market.
- Gross margin of 26.2%, indicating potential for profitability improvements with increased sales volume and cost management.
- Negative P/E ratio of -4.78, suggesting the company is currently unprofitable.
- Beta of 0.73, indicating lower volatility compared to the overall market.
- Profit margin of -205.3%, highlighting the need for improved operational efficiency and revenue generation.
Competitors & Peers
Strengths
- Proprietary Cxbladder technology for non-invasive bladder cancer detection.
- Established presence in key markets, including the United States, Australia, and New Zealand.
- Focus on early cancer detection and management.
- Developing diagnostic tools for multiple cancer types.
Weaknesses
- Negative profitability and reliance on external funding.
- Limited market share compared to larger diagnostic companies.
- Dependence on Cxbladder as the primary revenue source.
- Exposure to regulatory and reimbursement risks.
Catalysts
- Upcoming: Publication of new clinical data supporting the use of Cxbladder.
- Ongoing: Expansion of Cxbladder sales in the United States and other key markets.
- Ongoing: Development and commercialization of new cancer diagnostic tools.
- Upcoming: Securing favorable reimbursement policies for Cxbladder from healthcare providers.
- Ongoing: Strategic partnerships with healthcare providers and research institutions.
Risks
- Potential: Competition from established diagnostic companies with greater resources.
- Potential: Regulatory hurdles and changes in reimbursement policies.
- Potential: Technological advancements that could render Cxbladder obsolete.
- Ongoing: Reliance on Cxbladder as the primary revenue source.
- Ongoing: Negative profitability and need for additional funding.
Growth Opportunities
- Expansion in the United States: The US market represents a significant growth opportunity for Pacific Edge, driven by the high incidence of bladder cancer and the increasing adoption of non-invasive diagnostic methods. Securing favorable reimbursement policies and expanding the sales force in key regions could drive increased Cxbladder utilization. The US bladder cancer diagnostics market is estimated to be worth several billion dollars annually, providing a substantial addressable market.
- Development of New Cancer Diagnostics: Pacific Edge is developing diagnostic tools for other cancers, including colorectal, gastric, endometrial cancers, and melanoma. Successful development and commercialization of these new products would diversify the company's revenue streams and expand its market reach. The market for colorectal cancer diagnostics, for example, is projected to reach $4.5 billion by 2027.
- Strategic Partnerships: Collaborating with leading urology clinics and healthcare systems could accelerate the adoption of Cxbladder and provide access to a wider patient base. Strategic partnerships could also facilitate the development and commercialization of new diagnostic tools. These partnerships could involve joint research, co-marketing agreements, or distribution arrangements.
- International Expansion: Expanding into new international markets, such as Europe and Asia, represents another growth opportunity for Pacific Edge. These markets have a growing demand for advanced cancer diagnostics and could benefit from the non-invasive nature of Cxbladder. Regulatory approvals and market access strategies would be critical for successful international expansion.
- Increased Clinical Utility and Awareness: Generating additional clinical data to support the use of Cxbladder in various clinical settings could further drive adoption by urologists. Increasing awareness of Cxbladder among patients and healthcare providers through marketing and educational initiatives could also contribute to growth. This includes demonstrating the cost-effectiveness and improved patient outcomes associated with Cxbladder.
Opportunities
- Expansion in the United States and other international markets.
- Development and commercialization of new cancer diagnostic tools.
- Strategic partnerships with healthcare providers and research institutions.
- Increasing awareness and adoption of non-invasive cancer diagnostics.
Threats
- Competition from established diagnostic companies.
- Regulatory hurdles and changes in reimbursement policies.
- Technological advancements that could render Cxbladder obsolete.
- Economic downturns that could reduce healthcare spending.
Competitive Advantages
- Proprietary genomic urine test technology for bladder cancer detection.
- Established presence in the bladder cancer diagnostics market with Cxbladder.
- Focus on non-invasive diagnostic methods, offering advantages over traditional invasive procedures.
- Expanding portfolio of diagnostic tools for various cancers.
About PFGTF
Pacific Edge Limited, founded in 2001 and headquartered in Dunedin, New Zealand, is a cancer diagnostic company dedicated to researching, developing, and commercializing innovative diagnostic and prognostic tools. The company's primary focus is on the early detection and management of various cancers, with a strong emphasis on bladder cancer. Its flagship product, Cxbladder, is a suite of genomic urine tests designed to provide non-invasive methods for detecting and managing bladder cancer. Pacific Edge operates through two segments: Commercial and Research. The Commercial segment focuses on the sale and marketing of Cxbladder, while the Research segment is dedicated to developing new diagnostic and prognostic tools for various cancers, including colorectal, gastric, endometrial cancers, and melanoma. Cxbladder includes several tests: Cxbladder Triage, Cxbladder Detect, Cxbladder Monitor, and Cxbladder Resolve. These tests assist in identifying patients at low probability of having bladder cancer, detecting bladder and other urinary tract cancers, monitoring for recurrence, and identifying those likely to have aggressive forms of bladder cancer. Pacific Edge has expanded its reach to New Zealand, the United States, Australia, and Singapore, aiming to establish Cxbladder as a standard diagnostic tool for urologists.
What They Do
- Develop and commercialize diagnostic tools for early cancer detection.
- Offer Cxbladder, a suite of genomic urine tests for bladder cancer detection and management.
- Provide non-invasive methods for detecting and monitoring bladder cancer.
- Develop diagnostic products for colorectal, gastric, endometrial cancers, and melanoma.
- Operate in the Commercial and Research segments.
- Focus on early detection and management of cancers in New Zealand, the United States, Australia, and Singapore.
Business Model
- Generate revenue through the sale of Cxbladder tests to urologists and healthcare providers.
- Focus on commercializing diagnostic tools developed through research and development efforts.
- Seek reimbursement from healthcare providers and insurance companies for Cxbladder tests.
- Expand market reach through strategic partnerships and international expansion.
Industry Context
Pacific Edge operates within the medical diagnostics industry, a sector experiencing growth driven by advancements in genomic technologies and the increasing prevalence of cancer. The market is competitive, with established players like CORBF (Exact Sciences), LDXHF (Laboratory Corporation of America), ORXOF (Quest Diagnostics), PBIGF (PerkinElmer), and SHIEF (Siemens Healthineers) offering a range of diagnostic solutions. Pacific Edge differentiates itself through its focus on non-invasive urine-based cancer diagnostics, particularly for bladder cancer. The industry is characterized by stringent regulatory requirements, the need for continuous innovation, and the importance of securing reimbursement from healthcare providers.
Key Customers
- Urologists and other healthcare providers involved in the diagnosis and management of bladder cancer.
- Patients at risk of or diagnosed with bladder cancer.
- Hospitals and clinics offering cancer diagnostic services.
- Research institutions and pharmaceutical companies involved in cancer research.
Financials
Chart & Info
Pacific Edge Limited (PFGTF) stock price: Price data unavailable
Latest News
No recent news available for PFGTF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PFGTF.
Price Targets
Wall Street price target analysis for PFGTF.
MoonshotScore
What does this score mean?
The MoonshotScore rates PFGTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Peter Meintjes
CEO
Peter Meintjes serves as the CEO of Pacific Edge Limited, bringing extensive experience in the healthcare and diagnostics industries. His background includes leadership roles in various medical technology companies, where he focused on strategic planning, commercialization, and market development. Meintjes has a proven track record of driving growth and innovation in the healthcare sector. He is responsible for overseeing Pacific Edge's global operations and executing its strategic vision.
Track Record: Under Peter Meintjes' leadership, Pacific Edge has focused on expanding the commercial reach of Cxbladder and advancing the development of new cancer diagnostic tools. Key milestones include securing partnerships with leading urology clinics, expanding into new international markets, and generating clinical data to support the use of Cxbladder. Meintjes has also overseen efforts to improve operational efficiency and reduce costs.
PFGTF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pacific Edge Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and regulatory oversight.
- Lower liquidity and wider bid-ask spreads.
- Higher potential for volatility and price manipulation.
- Increased risk of fraud or misrepresentation.
- Potential for delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's liquidity and trading volume.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established presence in the bladder cancer diagnostics market.
- Proprietary Cxbladder technology.
- Peer-reviewed publications supporting the clinical utility of Cxbladder.
- Partnerships with leading urology clinics and healthcare systems.
- Experienced management team.
What Investors Ask About Pacific Edge Limited (PFGTF)
What does Pacific Edge Limited do?
Pacific Edge Limited is a cancer diagnostic company specializing in the development and commercialization of diagnostic and prognostic tools for the early detection and management of cancers. Their primary product, Cxbladder, is a suite of genomic urine tests designed for the non-invasive detection and management of bladder cancer. The company operates in the Commercial and Research segments, focusing on expanding the use of Cxbladder and developing new diagnostic solutions for various cancers.
What do analysts say about PFGTF stock?
AI analysis is currently pending for PFGTF, so analyst consensus is unavailable at this time. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Key valuation metrics to consider include the company's market capitalization, revenue growth, gross margin, and profitability. Growth considerations include the company's ability to expand Cxbladder sales, develop new diagnostic tools, and secure favorable reimbursement policies.
What are the main risks for PFGTF?
The main risks for Pacific Edge Limited include competition from established diagnostic companies, regulatory hurdles, and changes in reimbursement policies. The company also faces the risk of technological advancements that could render Cxbladder obsolete. Additionally, Pacific Edge is currently unprofitable and relies on external funding, which could pose a challenge if the company is unable to secure additional capital. Investing in OTC stocks carries additional risks, including limited financial disclosure and lower liquidity.
What are the key factors to evaluate for PFGTF?
Pacific Edge Limited (PFGTF) currently holds an AI score of 52/100, indicating moderate score. Key strength: Proprietary Cxbladder technology for non-invasive bladder cancer detection.. Primary risk to monitor: Potential: Competition from established diagnostic companies with greater resources.. This is not financial advice.
How frequently does PFGTF data refresh on this page?
PFGTF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PFGTF's recent stock price performance?
Recent price movement in Pacific Edge Limited (PFGTF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Cxbladder technology for non-invasive bladder cancer detection.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PFGTF overvalued or undervalued right now?
Determining whether Pacific Edge Limited (PFGTF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PFGTF?
Before investing in Pacific Edge Limited (PFGTF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for PFGTF, limiting the availability of analyst consensus and detailed financial analysis.
- OTC market investments carry higher risks due to limited regulation and potential for volatility.